They are advancing the obesity pill to phase 2 so they think it works good enough... the CEO at one stage said they are planning to sell it at a cheap and cheerful price to appeal to casual weight losers |
AstraZeneca shares hit a record high as US fast-tracks its blockbuster cancer drug Imfinzi
Daily Mail |
Blow to AstraZeneca vaccine project as Reeves plans funding cuts
Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant |
Indeed :-) |
And it is . |
MARKET REPORT: AstraZeneca tipped to become first £200bn British firm
Daily Mail |
NHS watchdog blocks AstraZeneca breast cancer drug |
LBBW raises AstraZeneca price target to 13,500 (13,300) pence - 'buy'
Goldman Sachs raises AstraZeneca price target to 15,756 (15,131) pence - 'buy' |
Robust results & a couple of decent late stage updates. Time to add |
Market report
One stock that fell victim to good not being ‘good enough’, XTB analyst Kathleen Brooks said, was AstraZeneca.
‘The market is scrutinizing earnings reports and punishing pockets of weakness,’ Brooks added, as the analyst said higher than expected costs may have been behind the 3.3% fall in the company’s shares.
The Cambridge-based pharmaceutical firm said total revenue in the first half of 2024 surged 15% to $25.62 billion from $22.30 billion. Pretax profit jumped 19% to $5.29 billion from $4.35 billion.
For the second-quarter alone, revenue climbed 13% $12.94 billion, and pretax profit was 15% higher at $2.40 billion.
Looking to the full-year, the pharmaceutical firm now expects total revenue and core EPS to grow by a ‘mid teens percentage’ at constant currency, its view upgraded from a previously expected ‘low double-digit to low teens rise’. |
On first look no disaster..
AstraZeneca lifted its full-year guidance as it reported an 18% increase in total revenue for the first half to $25.6bn, driven by significant growth in product sales and alliance revenue.
The FTSE 100 pharmaceuticals giant saw 22% growth in revenue from oncology, CVRM, and R&I, while rare disease revenue grew by 15%, with a core operating margin of 33% and a core earnings per share increase of 5% to $4.03.
AstraZeneca declared a seven-cent increase in its interim dividend and raised its full-year 2024 guidance, expecting mid-teens percentage growth in total revenue and core earnings per share at constant exchange rates. |
That's a rubbish response.
-3.3% |
Glad there wasn’t bad news |
Hope so. I have a £490k stake built up since 2009. Hope to hit the million mark fairly soon. Great co and CEO! |
Results tomorrow. |
Switched to RNK [better change to capital gains] 4 brokers issued strong BUY |
Money moved to APH [Alliance Pharma] |
aph quality poor, nowhere near the same outfit as eg AZN |
They raised APH ( alliance Pharma ) to BUY as well |
HSBC raises AstraZeneca price target to 14,070 (12,950) pence - 'buy' |
Goldman starts AstraZeneca with 'buy' - price target 15,200 pence |
Meanwhile Nvidia rises as much in a day as Astras market value , nuts . |
Stifel raises AstraZeneca price target to 13,700 (12,800) pence - 'buy' |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
![Logo of All Sports Coin [OLD] (SOCOUSD).](/common/images/company/COIN_SOCOUSD.png){kind=small}
